UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of October 2015

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

 

 

  

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033 and 333-204795), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

  

On October 26, 2015, Can-Fite BioPharma Ltd. (the “Company”) announced that it will hold a Special General Meeting of Shareholders on November 26, 2015 at 4.00 p.m. (Israel time) at the Company’s offices in Petach Tikva, Israel and a Special General Meeting of Series 10 Warrant Holders on November 26, 2015 at 4.30 p.m. (Israel time) at the Company’s offices in Petach Tikva, Israel. In connection with the meeting, the Company furnishes the following documents:

 

1. A copy of the Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders and Series 10 Warrant Holders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;
   
2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2;
   
3.

A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.3; and

 

4. A form of Proxy Card whereby holders of Series 10 Warrants of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.4.

  

 2 

 

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders and Series 10 Warrant Holders
     
99.2   Proxy Card for holders of ordinary shares with respect to the Company’s Special General Meeting of Shareholders
     

99.3

   Voting Instruction Card for American Depositary Share holders with respect to the Company’s Special General Meeting of Shareholders
     
99.4   Proxy Card for holders of Series 10 Warrants with respect to the Company’s Special General Meeting of Series 10 Warrants

 

 3 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.
     
Date October 26, 2015 By: /s/ Pnina Fishman
    Pnina Fishman
    Chief Executive Officer

 

 

 4